Management

board

Gur Roshwalb, MD, MBA, Chief Executive Officer
Click to read bio

Joined as CEO in March, 2013. From April 2008 to February 2013, Dr. Roshwalb was a Vice President at Venrock, where he was an investment professional on the healthcare team investing in both private and public companies. From May 2004 to March 2008, he was a vice president and equity analyst at Piper Jaffray, publishing research on specialty pharmaceutical companies. Prior to Piper, Dr. Roshwalb was in private practice in New York and Board Certified in Internal Medicine. He received his MD from Albert Einstein College of Medicine and his MBA from the NYU Stern School of Business. Dr. Roshwalb trained in internal medicine at the Mount Sinai medical center, where he also served as Chief Resident in 1997-1998.

Dr. Pablo Jimenez MD, Chief Medical Officer
Click to read bio

Dr. Jimenez is a senior pharmaceutical executive with more than twenty years of success in clinical development and medical affairs within the dermatology, respiratory, wound healing and oncology therapeutic areas. He brings a strong background in product business development in inflammation, and immunology. Dr. Jimenez is a successful global developer of industry-leading pharmaceutical products. His career spans all levels of development and medical Affairs, including global roles in the Biopharmaceutical industry (Sotio a. s. Human Genome Sciences, Neronyx and OsteoArthritis Sciences.) Dr. Jimenez worked at Novartis from May 2001 – September 2011 in Novartis Pharma Clinical Development and Medical Affairs, and he held positions of increasing responsibility including: Global Clinical Program Leader Apligraf®, Global Project Section Leader Elidel®, Global Brand Medical Director Xolair®, Global Head, Medical Services and Global Head of Medical Education & Communications. . From September, 2011 to March, 2012, Dr. Jimenez was employed by Sotio, a Czech drug development company, as their Chief Medical Officer, where he was responsible for their global clinical portfolio, including clinical development, marketing strategy and regulatory compliance. From July 2012 to present, he has served as the founder and CEO of Qara Bio-Pharmaceutical Solution, LLC, a boutique medical writing and drug development strategy consulting firm. He received his MD from Central University School of Medicine in Ecuador and Master’s Certificate in Project Management from the George Washington University School of Business and Public Management. Dr. Jimenez did his Post-Doctoral research work at Brown University, Division of Biology and Medicine.

Mr. Dov Elefant, Chief Financial Officer
Click to read bio

Has served as our Chief Financial Officer since January 11, 2012. From March 2011 until January 2012, he was Chief Financial Officer of Althera Medical Ltd. and from March 2009 to February 2011 he performed consulting services to a number of companies. He was also the Corporate Controller, from March 2007 to February 2009 for Lev Pharmaceuticals (OTCBB:LEVP), which was acquired by ViroPharma in 2008,Controller and Vice President of Finance and Administration at EpiCept Corporation (NASDAQ:EPCT.PK) from December 1999 to March 2007,Assistant Controller at Tetragenex Pharmaceuticals from November 1998 to October 1999 and held other accounting and finance roles from March 1991 to October 1998. Mr. Elefant holds a B.S. in accounting from Yeshiva University

Nicolas Mourier, Ph.D., Senior Vice President Chemistry, Manufacturing and Control (CMC)
Click to read bio

Dr. Mourier has worked in the biopharmaceutical industry and academia for over 20 years and is broadly experienced in all the CMC aspects of small molecules, peptides, polymers and proteins from preclinical to commercial. Most recently, Dr. Mourier was a consultant for small and large biotechnologies companies assuming various cross functional roles as subject matter expert. Prior to that, Dr. Mourier was the CMC head at Peptimmune, where he oversaw all the pharmaceutical development activities that successfully lead to lifting a partial clinical hold allowing the authorization to initiate an international phase II clinical trial of their copolymer lead product PI-2301. Dr. Mourier has also assumed key role functions in several CROs and CMOs for the manufacturing, analytical and formulation development of early and late stage products. He received his Ph.D. in organic chemistry with honors from the University of Luminy (Marseille, France) under the supervision of Pr. Chermann (Co-discoverer of the HIV virus at the Pasteur Institute in Paris, France).